ALPMY - KaliVir Immunotherapeutics inks agreement with Astellas for development and commercialization of VET2-L2

KaliVir Immunotherapeutics has entered into a worldwide licensing agreement for the research, development, and commercialization of VET2-L2 with Astellas Pharma (ALPMY)Under the terms of the agreement, Astellas will pay to KaliVir up to $56M in the form of an upfront payment and other payments to support research and preclinical activities related to VET2-L2 and the second product.Additionally, Astellas may pay up to $307M and up to $271M for development, regulatory and commercialization of VET2-L2 and Second Product, respectively.Astellas also may make royalty payments on net sales of each licensed product.KaliVir's expertise in the development of oncolytic viruses along with Astellas' capabilities in advanced drug development and its global business experience, will enable both parties to develop new Immuno-Oncology therapies. ALPMY is +0.2% to $14.44Source: Press Release

For further details see:

KaliVir Immunotherapeutics inks agreement with Astellas for development and commercialization of VET2-L2